Share on StockTwits

ResMed (NYSE:RMD) CFO Brett Sandercock sold 4,290 shares of the stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $50.00, for a total transaction of $214,500.00. Following the completion of the sale, the chief financial officer now directly owns 71,423 shares of the company’s stock, valued at approximately $3,571,150. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

ResMed (NYSE:RMD) traded up 0.04% on Thursday, hitting $49.99. The stock had a trading volume of 732,225 shares. ResMed has a 52 week low of $41.52 and a 52 week high of $57.34. The stock’s 50-day moving average is $46.48 and its 200-day moving average is $47.03. The company has a market cap of $7.015 billion and a price-to-earnings ratio of 21.93.

ResMed (NYSE:RMD) last posted its quarterly earnings results on Wednesday, April 23rd. The company reported $0.63 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.64 by $0.01. The company had revenue of $397.80 million for the quarter, compared to the consensus estimate of $401.00 million. During the same quarter last year, the company posted $0.58 earnings per share. ResMed’s revenue was up 3.7% compared to the same quarter last year. Analysts expect that ResMed will post $2.49 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which is scheduled for Tuesday, June 17th. Shareholders of record on Tuesday, May 20th will be given a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a yield of 2.00%. The ex-dividend date of this dividend is Friday, May 16th.

A number of research firms have recently commented on RMD. Analysts at Deutsche Bank upgraded shares of ResMed from a “hold” rating to a “buy” rating in a research note on Thursday, April 24th. They now have a $52.00 price target on the stock. Separately, analysts at Morgan Stanley reiterated an “equal weight” rating on shares of ResMed in a research note on Thursday, April 24th. They now have a $46.08 price target on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of ResMed in a research note on Monday, March 10th. They now have a $46.00 price target on the stock. Nine analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $46.64.

ResMed Inc, (NYSE:RMD) is a holding company for the ResMed Group.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.